How Proteins Change Shape: A New Theory for Why Type 1 Diabetes Develops

For decades, researchers assumed that autoimmune diseases like Type 1 diabetes happen when the immune system simply fails to tolerate our own proteins. But this explanation has gaps. If the problem were just 'self' proteins, why do only certain people develop the disease? Why do symptoms sometimes appear after infections or stressful events? Why do specific genetic markers increase risk?

A growing body of research suggests the answer lies not in the proteins themselves, but in how they are modified after they are made. These changes, called posttranslational modifications, can alter a protein's shape, charge, and chemistry—potentially making it unrecognizable to the immune system in new ways.

Proteins don't stay exactly as they are when first created. They can be chemically altered in numerous ways. Some modifications add small chemical groups—like phosphate groups (phosphorylation) or sulfate groups (sulfation). Others change the protein's structure more dramatically, such as deamidation, which alters amino acids in the protein chain.

Oxidation can occur when proteins are exposed to stress or inflammation. Glycosylation adds sugar structures to proteins. Even more unusual modifications include the removal of signal peptides that normally guide proteins, specialized trimming by enzymes, or the joining of protein fragments that don't normally belong together. Protein clumping, or aggregation, can also change how the immune system recognizes and responds to these molecules.

In Type 1 diabetes specifically, scientists have identified hybrid insulin peptides—fragments of insulin protein that have been recombined in unusual ways—as targets of immune attack. These modified forms may not resemble the 'normal' insulin the body originally learned to tolerate.

The question remains: what triggers these protein modifications in the first place? Research suggests that stress, infection, or inflammation may cause cells to produce modified versions of normally tolerated proteins. Once these altered forms appear, the immune system may recognize them as threats and mount an attack.

Genetic factors, including specific HLA types, may determine whose immune systems are more likely to detect and react to these modified proteins. This could explain why Type 1 diabetes runs in families but doesn't affect everyone who carries the same genes.

Identifying the exact modified proteins that the immune system attacks in Type 1 diabetes is a major research priority. Advanced techniques like mass spectrometry and immunopeptidomics—which map which protein fragments the immune system actually recognizes—are making this possible.

If scientists can pinpoint which modified antigens drive Type 1 diabetes, they may be able to develop tests that catch the disease earlier, predict who is at highest risk, or even design new preventive strategies. This shift from studying proteins as they should be to studying proteins as they actually are could fundamentally change how we understand and treat autoimmune disease.

Source: Immunological reviews. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.